http://www.metastat.com/ 150,000,000 shares authorized; 21,469,435 and 21,054,418 shares issued and outstanding respectively
MetaStat, Inc. (OTCQB: MTST) is a development stage life sciences company headquartered in Montclair, New Jersey. We are focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis - cancer that spreads from a primary tumor through the bloodstream to other areas of the body. Systemic metastasis is responsible for ~90% of all solid tumor cancer related deaths and as such, we believe that more effective treatment of metastatic disease and/or the prevention of systemic metastasis is needed to improve patient outcomes.
Our licensed proprietary platform technologies are based on the identification of a common pathway for the development of metastatic disease in solid epithelial-based tumors. These discoveries are the result of over 15 years of collaboration with four scientific/academic institutions that enabled us to understand the underlying biology and mechanisms of systemic metastasis. Central to these discoveries are i) the “MetaSite™,” the micro-anatomical site, or “window” in the blood vessels that metastatic cells squeeze through to enter the blood stream to begin their deadly spread, and ii) the pivotal role of the Mena protein and its isoforms in the metastatic cascade.
We are developing two function-based diagnostic product lines, MetaSite Breast™ and MenaCalc™. The MetaSite Breast™ test measures the process of systemic metastasis and is intended for early stage breast cancer patients. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. Both our MetaSite Breast™ and MenaCalc™ diagnostics are designed to accurately predict the probability of systemic metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of systemic metastasis who need aggressive therapy and by sparing patients with a low-risk of systemic metastasis from the harmful side effects and expense of chemotherapy. Douglas A. Hamilton, B.Sc., MBA President and Chief Executive Officer Mr. Hamilton was appointed President and Chief Executive Officer of the company on June 17, 2015 and has consulted for the company as acting Chief Financial Officer since August 2014. Mr. Hamilton has over 20 years experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as CFO for SEA Medical Systems, a Silicon Valley health-tech company that developed medical devices designed to enhance patient safety by preventing medication errors. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing, Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox® and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend® and Zithromax® product teams at Pfizer, in addition to the Aranesp®, Epogen®, Stemgen®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University. Michael J. Donovan, PhD, MD Chief Medical Officer Dr. Donovan joined the company as acting chief medical officer in August 2015. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid-based assays and coupled mathematic applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York. In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of Exosome Diagnostics, Inc. and Chief Scientific Officer for Aureon Biosciences Corporation. Dr. Donovan graduated from Rutgers University with a BS in zoology, a MS in endocrinology and a PhD in cell and developmental biology. He received his MD from the University of Medicine and Dentistry of New Jersey. Mark Gustavson, Ph.D. Vice President of Diagnostics Dr. Gustavson joined the company as Vice President of Diagnostics in August 2014. Dr. Gustavson has more than 10 years of experience in translational oncology, biomarker and diagnostics development, and quantitative pathology. Prior to joining the company, Dr. Gustavson was a Consultant for Oncology Biomarker Development at Genoptix Medical Laboratory. From 2006 to 2012, Dr. Gustavson was with HistoRx, Inc. where he played a central role in the development and commercialization of the quantitative pathology platform, AQUA® Technology. With HistoRx, Dr. Gustavson served as Director of Operations where he oversaw assay and platform development as well as clinical validation of the breast cancer diagnostic test, IHC4. Dr. Gustavson did his post-doctoral fellowship at Yale University and received his Ph.D. in Cancer Biology from Vanderbilt University School of Medicine. Dr. Gustavson has over 40 peer-review publications and abstracts, and 9 patents. Daniel H. Schneiderman Vice President of Finance & Corporate Secretary Daniel H. Schneiderman was appointed Vice President of Finance effective December 21, 2012 and has served as the company's Vice President, Comptroller and Corporate Secretary since February 27, 2012. Mr. Schneiderman has over ten years of investment banking and corporate finance experience, focusing on private and public equity for small and mid-market capitalization companies mainly in the healthcare and life sciences sectors. Prior to joining the company, he was senior vice president of investment banking for Burnham Hill Partners LLC, where he worked since 2008. From 2004 through 2008, Mr. Schneiderman was vice president of investment banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, he worked at H.C. Wainwright & Co. in 2004 as an analyst. Mr. Schneiderman holds a Bachelor's Degree from Tulane University. Heiner Dreismann, Ph.D. Diagnostic Consultant Dr. Dreismann joined the company as a consultant (head of diagnostics) in October 2013. Dr. Dreismann is a seasoned executive with more than 24 years of experience in the health care industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
Additionally, we are developing our MenaBloc™ therapeutic platform, with the goal of discovering inhibitors of key pathways that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.